Products - Dementia | Topic | NICE

Showing 7 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
20 June 2018
Published:
23 March 2011
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
5 February 2025
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
26 March 2025
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
30 April 2025
Gantenerumab for treating early Alzheimer's disease TS ID 10668
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Alzheimer's disease (early) - gantenerumab [ID6142]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pridopidine for treating Huntington's disease TSID 12052
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC